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PREVENTION AND INFECTION CONTROL FOR NOROVIRAL INFECTION
Cheng-Hsun Chiu, MD, PhD. Division of Pediatric Infectious Diseases, Chang
Gung Children’s Hospital, Chang Gung University College of Medicine,
Taoyuan, Taiwan
Norovirus, a genus within the Caliciviridae family, is the leading cause of
sporadic and epidemic acute gastroenteritis worldwide. Our understanding
of norovirus epidemiology has significantly progressed in recent years due
to the development of sensitive molecular diagnostic techniques. We now
understand that human noroviruses are extremely diverse, with three gen-
ogroups (GI, GII, and GIV), at least 25 genotypes, and numerous subgeno-
types or variants identified in the past two decades. In recent years, only
a few strains, primarily those of genogroup II, genotype 4 (GII.4) have
been responsible for the majority of outbreaks. Norovirus genotype GII.4 is
responsible for the majority of outbreaks, but new variants are continuously
emerging. Noroviruses are found in the feces and vomit of infected people.
This virus is very contagious and can spread rapidly throughout healthcare
facilities. People can become infected with the virus in several ways: 1) Hav-
ing direct contact with another person who is infected; 2) Eating food or
drinking liquids or water that are contaminated with norovirus; 3) Touching
surfaces or objects contaminated with norovirus, and then touching your
mouth or other food items. In a healthcare facility, patients with suspected
norovirus may be placed in private rooms or share rooms with other patients
with the same infection. Additional prevention measures in healthcare facil-
ities can decrease the chance of coming in contact with noroviruses: 1)
Follow hand-hygiene guidelines, and carefully washing of hands with soap
and water after contact with patients with norovirus infection; 2) Use gowns
and gloves when in contact with, or caring for patients who are symptomatic
with norovirus; 3) Routinely clean and disinfect high touch patient surfaces
and equipment with an authority-approved product with a label claim for
norovirus; 4) Remove and wash contaminated clothing or linens; and 5)
Healthcare workers who have symptoms consistent with norovirus should
be excluded from work. A norovirus vaccine is being developed for active
prevention of the infection in children as well as in adults.SYMPOSIUM 5 (SP 5)
CURRENT MANAGEMENT OF FUNGAL AND VIRAL INFECTIONSSP 5-1
INFECTIONS CAUSED BY RARE FUNGI
Jacques F. Meis. Department of Medical Microbiology and Infectious
Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands;
Department of Medical Microbiology, Radboud University Medical Center,
Nijmegen, The Netherlands
The predominant nosocomial fungal pathogens are Candida spp., and
Aspergillus spp. but rare and emerging fungi are increasingly being reported,
also among Candida and Aspergillus genera and species complexes. These
rare pathogens are mostly seen in severely immunocompromised hosts. The
presentation will focus on Cryptococcus gattii, newly recognized yeast spp,
black yeasts, Exserohilum, and Penicillium spp. Rapid taxonomic changes are
a hallmark of these fungi. Especially for epidemiological purposes, including
outbreak investigation, molecular identification is indispensible. Rare fungal
pathogens are often resistant to one or more antifungal drugs.SP 5-2
CURRENT MANAGEMENT OF CHRONIC HEPATITIS C
Owen Tak Yin Tsang. Infectious Disease Centre, Princess Margaret Hospital,
Hong Kong Special Administrative Region
Chronic hepatitis C is a global disease. An estimated of 150 millions people
worldwide are chronically infected and around 350,000 to 500,000 people
die each year from hepatitis C related liver diseases. Around 15% to 30% of
patients with chronic hepatitis C will develop cirrhosis in 20 years. The risk
of development of hepatocellular carcinoma would be about 1e4% per yearonce the patient has progressed to cirrhosis. The prevalence of chronic
hepatitis C is the highest in Asia Pacific region. It varies from 1% in Southeast
Asia to 5.4% in Central Asia. Chronic hepatitis C also accounts for a
significant proportion of patients requiring liver transplantation as a result
of decompensation or development of hepatocellular carcinoma. There are
altogether 6 genotypes of hepatitis C worldwide and genotype 1 is most
common of all infections, followed by genotypes 2 & 3. Genotype 6a is
particularly prevalent in Southeast Asia, accounting for over 50% in countries
like Cambodia or Vietnam. This genotype is also exclusively common in
intravenous drug abusers. The management of chronic hepatitis C has
evolved extensively over the years. Combination therapy with pegylated
Interferon and ribavirin has been the standard of care for more than 10
years. An over 80% sustain virological response rate (SVR) can be achieved
for patients infected with genotype 2 and 3 after half year treatment of this
regime. However, the SVR for genotype 1 after this combo can only fall
around 50% even with 48 weeks of therapy. Moreover, significant side effects
from the combination including flu-like symptoms, fever, myalgia, malaise,
cough, allergic reactions, cytopenia, thyroid diseases, alopecia or insomnia
can be anticipated. In response to these caveats, researchers has devoted to
develop new antivirals targeting directly on the virus itself, so called the
Direct-acting Antivirals (DAAs), with an aim of increasing efficacy and
enhancing tolerability & safety. The first generation DAAs include boceprevir
and telaprevir. When these medications are used in combination with the
pegylated interferon and ribavirin, a 10e20% increase in SVR can be
achieved in genotype 1-treatment naı¨ve patients. SVR in difficult-to-treat
patients such as previous non-responders to dual therapy is still disap-
pointing. Moreover, the added side effects including aggravation of anemia,
dysguesia and enhanced allergic reaction can be difficult to overcome.
Interferon-free regime is then a very attractive strategy of therapy.
Sofosbuvir is the first compound ever produced to be the interferon-free
treatment. When it is combined with other antivirals for different geno-
types, an extraordinary SVR of 80% to even over 90% can be attained. The
rapid development of hepatitis C medications is unprecedented. There are
at least 10 novel medications on the pipeline to enter this treatment arena.
The future eradication of hepatitis C virus may be anticipated.SP 5-3
CURRENT MANAGEMENT OF HIV INFECTION
Chien-Ching Hung. National Taiwan University College of Medicine, Taipei,
Taiwan
No abstract.
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NATIONAL IMPLEMENTATION OF ANTIMICROBIAL STEWARDSHIP
PROGRAMS
Marilyn Cruickshank. Faculty of Nursing and Midwifery, Griffith University,
Queensland, Australia
A snap shot survey conducted in 2008 of AMS programs in Australian hospitals
reported only 11% of hospitals had a fully integrated AMS program in place
that was overseen by a central body or committee; only 67% used guidelines
to guide antimicrobial prescribing, and only 47% did regular audits of
antimicrobial prescribing (Chen 2011).
The National Safety and Quality Health Service (NSQHS) Standards were
designed to protect the public from harm and to improve the quality of care
to patients. In implementing the NSQHS Standards, health services have put
in place safety and quality systems to ensure standards of care are met and
quality improvement mechanisms exist. This includes the implementation of
Antimicrobial Stewardship (AMS) programs in every hospital and day proce-
dure service in Australia.
Since the implementation of Standard 3, 100% of health services accredited
to date have a fully developed AMS program, all prescribers have access to
antibiotic guidelines, and, all health services monitor their use of antibiotics.
While some countries have developed guidelines and strategies for AMS
program, many are yet to include specific requirements for the management
of antibiotic resistance and usage Australia leads the world in mandated
requirements for infection prevention and control and AMS in health services
S14 Abstracts of the 7th International Congress of the Asia Pacific Society of Infection Control, Taipei, Taiwan, March 26-29, 2015safety and quality standards. The Australian Commission on Safety and
Quality in Health Care has developed resources that assist health services
implement these important initiatives.
The introduction of these requirements have been ‘transformative’ in that it
provides the necessary stimulus for hospital executives to re-prioritise and
commit resources to the prevention of healthcare associated infections as
well as accept responsibility for governance.
Chen AWJ, Khumra S, Eaton V, Kong D Snapshot of antimicrobial stewardship
in Australian hospitals Journal of Pharmacy Practice and Research Volume
41, No. 1, 2011SP 6-2
SURVEILLANCE SYSTEM OF ANTIMICROBIAL RESISTANCE AND
HEALTHCARE-ASSOCIATED INFECTIONS IN JAPAN
Satowa Suzuki, M.D., Ph.D. Chief, Laboratory of Antibiotics and Resistance,
Department of Bacteriology II. National Institute of Infectious Diseases,
Japan
Antimicrobial resistance (AMR) is of global concern, and strengthening
surveillance is critical. Japan has two major surveillance for AMR. The first
one is National Epidemiological Surveillance of Infectious Disease (NESID),
which is a national comprehensive surveillance system under infection control
act. About 110 infectious diseases including seven AMRbacterial infections are
designated as reportable disease. The second one is Japan Nosocomial Infec-
tions Surveillance（JANIS）, which has been established in 2000 as a volun-
tary-based national surveillance system targeting healthcare-associated
infections and antimicrobial resistant bacteria. It is organized by Ministry of
Health Labour andWelfare, and JANIS management office located at National
Institute of Infectious Diseases. More than 1600 hospitals are participating to
JANIS on voluntary basis as of January 1st, 2015.
JANIS consist of five divisions and Clinical Laboratory division provides
information on prevalence of AMR bacteria among clinical isolates. JANIS
collects data from hospital laboratories that have an automated system for
bacterial identification and drug susceptibility testing, and also data from
commercial laboratories to which participating hospitals are contracted.
Following conversion of those laboratory data into JANIS data format, the
data is collected to a centralized JANIS database server for analysis.
Collected data would be processed by JANIS tabulation program, which
was developed by JANIS research team, to detect data error, remove
duplicate samples and differentiate drug susceptibility pattern by an original
algorithm. JANIS has been working for years to standardize JANIS data
format and establish tabulation program. The outputs from this JANIS system
include aggregate AMR data by hospital to allow for inter-hospital compar-
ison as well as national data for AMR trends. From 2014, JANIS starts to
recruit hospitals outside Japan to participate this surveillance system.
In the presentation, a summary of JANIS annual report 2013 which is based
on data of 4.6 million samples and 3.6 million isolates submitted from 745
hospitals across Japan would be provided.SP 6-3
IMPLEMENTATION OF BUNDLE CARE TO DECREASE HEALTHCARE
ASSOCIATED INFECTIONS IN TAIWAN
Wang-Huei Sheng a,b,*, Yee-Chun Chen a,b, I-Chen Hung a,
Ying-Ying Chang a, Yu-Ching Chang a, Mei-Chuan Hung a, Ya-Hui Huang a,
Kwei-Lien Tien a, Hsin-Hsin Chang a. aDepartment of Internal Medicine,
National Taiwan University Hospital, Taipei, Taiwan; bInfection Control
Center, National Taiwan University Hospital, Taipei, Taiwan
Health care-associated infections (HAI) are associated with significant
morbidity at hospitals. We implemented active surveillance, hand hygiene
promotion, isolation cohort of resistant microorganism and bundle care since
2010. The bundle care program includes prevention care of center-line
associated bloodstream infection, urinary catheter associated urinary tract
infection, ventilator-associated pneumonia, and surgical wound infection. The
infection density decreased from5.1 per 1000 patient-days in 2011, 4.9 in 2012,
4.2 in 2013, and 3.7 in 2014, respectively. Infection density of methicillin-
resistant Staphylococcus aureus had decreased from0.18 per 1000 patient-days
in 2011 to 0.11 in 2014. Infection density of carbapenem-resistant Acineto-
bacter baumannii had had decreased from 0.15 per 1000 patient-days (&) in2011, 0.18 in 2012, 0.09 in 2013 and 0.07 in 2014 (P<0.001). A infection control
environment reduce the morbidity, mortality and medical costs. Implementa-
tion of bundle care has shown successful to decrease HAI in Taiwan.
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CLOSTRIDIUM DIFFICILE INFECTION IN WESTERN COUNTRIES: UNDER
DIAGNOSES, EPIDEMIOLOGY & EVOLVING THERAPIES
Ellie J. C. Goldstein, MD. RM Alden Research Laboratory and UCLA School of
Medicine, Los Angeles, CA, United States
C difficile associated infection (CDI) effects approximately 500-e700,000
Americans annually and is associated with significant and recently increasing
morbidity and mortality with 7,285 deaths reported in 2009. CDI also has a
substantial economic impact. The cost of treating one CDI patient in hospital
is approximately $8,000. Annual expenditures in the USA to manage CDI is
$3.2 billion/year, not including measures taken to prevent the spread of
C. difficile spores. Because of lack of suspicion and/or laboratory methodo-
logical issues it seems likely that CDI is underdiagnosed worldwide. It is esti-
mated that 40,000 cases per year are missed in European countries. Of
336,600 hospitalizations in the US, 1% of all stays develop CDI. Rates vary
for HO-HCFA CDI from rates 2.8-e9.3 per 10,000 patient days, to 1.3-e2.7
CO-HCFA and 20-e30 per 100,000 population for CA-CDI. In the USA stool cul-
ture for C. difficile is not performed and therefore epidemiological surveys
rely on data from a few centers. Between 2011-2013, 29 ribotypes types
were identified with 027 most frequent and accounting for 28.1% although
rates varied by geographic region. Ina survey of 20 European countries,
027 was the most prevalent ribotype (w18%) but varied by country for 43%
in Germany to 12% in Romania.
The therapy foe CDI has been stagnant for approximately 30 years with the
only alternatives being metronidazole or oral vancomycin. Because relapse
rates range between 20e30 %, especially in the elderly and medically
vulnerable, there has been a search for both new and more effective
therapeutic agents as well as novel preventative strategies. A recent study
(CID 2014) notes the inferiority of both metronidazole and vancomycin
compared to fidaxomicin in mild, moderate and severe CDI with statistically
superior sustained cure especially in various patient groups at greater risk of
relapse such as patients requiring concomitant antibiotics and those with
renal failure. Several new agents surotomycin, (CB-183315), SMT19969,
cadazolid and others are currently in development for CDI therapy. Other
promising alternative therapeutic approaches include monoclonal anti-
bodies, fecal biotherapy, oral spore ingestion, vaccination, and the use of
probiotics for primary prevention.SP 7-2
HYPERVIRULENT CLOSTRIDIUM DIFFICILE IN ASIA
Deirdre A. Collins a, Thomas V. Riley a,b,*. aMicrobiology & Immunology, The
University of Western Australia, Nedlands 6009, Western Australia;
bDepartment of Microbiology, PathWest Laboratory Medicine (WA), Queen
Elizabeth II Medical Centre, Nedlands 6009, Western Australia, Australia
While Clostridium difficile infection (CDI) has come to prominence as ma-
jor epidemics have occurred in North America and Europe over the last 15
years, awareness and surveillance of CDI in Asia have remained poor.
Limited studies performed throughout Asia indicate that CDI is also a sig-
nificant nosocomial pathogen in this region, but the true prevalence of CDI
remains unknown. A lack of regulated antibiotic use in many Asian coun-
tries suggests that the prevalence of CDI may be comparatively high. Mo-
lecular studies indicate that ribotypes 027 and 078, which have caused
significant outbreaks in other regions of the world, are rare in human
CDI in Asia, however, there have been no published investigations of pro-
duction or companion animals in the region. Variant toxin A-negative/
toxin B-positive strains of ribotype 017 caused apparent epidemics across
several Asian countries in the mid-2000s but now appear to be waning.
Ribotype smz/018 has caused widespread disease across Japan over the
last decade and more recently emerged in Korea. Both ribotype 17 and
18 have caused major outbreaks outside Asia highlighting the potential
for transfer to different countries. Better surveillance for CDI in Asia is
essential, and urgently required.
